NCT03562117View on ClinicalTrials.gov

Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 14, 2018

Primary Completion Date

December 26, 2018

Study Completion Date

December 26, 2018

Conditions
Infections, Bacterial
Interventions
DRUG

Gepotidacin

It is an immediate-release tablet (1500 mg (2 x 750 mg), containing gepotidacin (free base) an inactive formulation excipients.

Trial Locations (2)

32809

GSK Investigational Site, Orlando

33136

GSK Investigational Site, Miami

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

GlaxoSmithKline

INDUSTRY

NCT03562117 - Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function | Biotech Hunter | Biotech Hunter